Intra-Cellular Therapies Inc.

Historical 13F Holders

Symbol
ITCI
CUSIP
46116X101
All holders as of
Q2 2026
Type
Equity
Class
COM
Reported Value, Excluding Options
Total Shares Held, Excluding Options
Total Filers

13D/G Filers

Each filer's latest filing for 46116X101 since 12/18/2024, largest first.

Filer % of Class Filed
Under 5%, checked the "5 percent or less" box, or amended by a later filing (2)
FMR LLC 13G/A
2.5% 2/7/2025
Event 1/31/2025
JPMorgan Chase & Co 13G/A 0% 6/5/2025
Event 5/30/2025

13F Holders by Quarter

Period Filers Shares, Excl. Options Value, Excl. Options
2026 Q2 1 1.00 $2.54k
2026 Q1 1 1.00 $2.54k
2025 Q4 1 1.00 $2.54k
2025 Q3 1 1.00 $2.54k
2025 Q2 4 52.8 k $4.15M
2025 Q1 401 103 M $13.6B
2024 Q4 394 96.8 M $8.08B
2024 Q3 360 97.2 M $7.12B
2024 Q2 379 96.6 M $6.62B
2024 Q1 354 88.9 M $6.15B
2023 Q4 341 89.6 M $6.42B
2023 Q3 298 87.2 M $4.54B
2023 Q2 293 84.4 M $5.34B
2023 Q1 280 83.9 M $4.55B
2022 Q4 286 83.3 M $4.41B
2022 Q3 278 83.5 M $3.89B
2022 Q2 270 81.5 M $4.65B
2022 Q1 245 80.8 M $4.96B
2021 Q4 215 69.0 M $3.60B
2021 Q3 183 68.6 M $2.56B
2021 Q2 192 67.0 M $2.74B
2021 Q1 172 68.0 M $2.30B
2020 Q4 181 67.1 M $2.14B
2020 Q3 179 63.8 M $1.63B
2020 Q2 156 48.8 M $1.25B
2020 Q1 143 48.0 M $755M
2019 Q4 143 38.0 M $1.30B
2019 Q3 135 39.8 M $298M
2019 Q2 137 38.4 M $498M
2019 Q1 134 38.4 M $469M
2018 Q4 135 37.9 M $432M
2018 Q3 136 38.3 M $832M
2018 Q2 133 39.8 M $704M
2018 Q1 133 39.4 M $829M
2017 Q4 133 38.2 M $553M
2017 Q3 140 40.8 M $643M
2017 Q2 103 31.0 M $385M
2017 Q1 121 29.3 M $476M
2016 Q4 132 30.1 M $455M
2016 Q3 135 27.9 M $425M
2016 Q2 141 30.5 M $1.19B
2016 Q1 128 29.4 M $818M
2015 Q4 133 28.5 M $1.53B
2015 Q3 130 27.9 M $1.12B
2015 Q2 92 18.1 M $577M
2015 Q1 74 17.0 M $405M
2014 Q4 47 12.2 M $216M
2014 Q3 49 12.1 M $166M
2014 Q2 55 12.1 M $204M
2014 Q1 35 11.0 M $201M